secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-08-17T13:05:22+00:00
Accession:  0001140361-26-033282
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio secondary offering: KKR sells 5M shares at $78, no proceeds to company
--------------------------------------------------------------------------------

- KKR Genetic Disorder L.P. selling 5,000,000 shares at $78.00/share; expected close Aug 17, 2026.
- Company receives no proceeds; offering oversubscribed per Aug 14 press release.
- Joint book-runners: William Blair, Goldman Sachs & Co. LLC, KKR Capital Markets LLC.
- Offering launched Aug 13, priced Aug 14; aims to diversify shareholder base toward long-term ownership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126033282/0001140361-26-033282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126033282/ef20080234_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-033282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer